Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. Since its inception in 2003, the Company's strategic intent has been to acquire the technologies needed to deliver on that mission within high value markets. The foundation of the Company's approach is the premise that effective management of inflammation and immunity can dramatically improve clinical outcomes. Recently, the Company in-licensed a group of vaccine-based technologies that greatly accelerate its ability to deliver products using two principle approaches -- therapeutic vaccination and immunotherapeutics.